Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035596 | 0.95 | TSHR (0.48) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL194803 | 0.85 | TSHR (0.57) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL11687302 | 0.83 | TSHR (0.55) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL7934188 | 0.81 | TSHR (0.52) | TSHRIDO1AGXTALDH1A1CA1 | |
| Bromide SCHEMBL11675628 | 0.81 | TSHR (0.52) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL17171596 | 0.80 | TSHR (0.52) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL28546168 | 0.78 | TSHR (0.44) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL1117737 | 0.78 | TSHR (0.55) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL9052472 | 0.77 | TSHR (0.48) | TSHRIDO1AGXTALDH1A1CA1 | |
| Carbon Monoxide SCHEMBL11680342 | 0.77 | TSHR (0.48) | TSHRIDO1AGXTALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109320552-B | Puerarin derivative with good biological activity and preparation method and application thereof | 浙江药苑生物科技有限公司 | 2020-10-16 | — | — | CN | claimed |
| CN-109320552-A | With active puerarin derivate of good biological and preparation method thereof and application | 余代英 | 2019-02-12 | — | — | CN | claimed |
| US-20040127467-A1 | Synthesis of pancratistatin prodrugs | ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2004-07-01 | — | — | US | claimed |
| EP-1385846-A2 | SYNTHESIS OF PANCRATISTATIN PRODRUGS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA acting for and on behalf of ARIZONA STATE UNIVERSITY (US) | 2004-02-04 | — | — | EP | claimed |
| WO-2002085848-A2 | SYNTHESIS OF PANCRATISTATIN PRODRUGS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2002-10-31 | — | — | WO | claimed |
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | APOAPSIS HOLDINGS, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-12570621-B2 | Short-acting 3,4-methylenedioxymethamphetamine (MDMA) analogs incorporating benzothiazole | APOAPSIS HOLDINGS, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4583865-A1 | SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE | Mydecine Innovations Group Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12358919-B2 | Antibacterial compounds | UNIVERSITA' DEGLI STUDI DI SIENA (IT) | 2025-07-15 | — | — | US | disclosed |
| US-20250207163-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | TRILINK BIOTECHNOLOGIES, LLC | 2025-06-26 | — | — | US | disclosed |
| US-20250121067-A1 | WATER-SOLUBLE CANNABINOID PRODRUGS COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | TRAIT BIOSCIENCES INC (US) | 2025-04-17 | — | — | US | disclosed |
| EP-4531836-A1 | WATER-SOLUBLE CANNABINOID PRODRUGS COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | Trait Biosciences, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2002036576-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
| EP-1045853-A4 | SYNTHESIS OF COMBRETASTATIN A-4 PRODRUGS AND TRANS-ISOMERS THEREO F | UNIV ARIZONA STATE (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001081355-A1 | COMBRETASTATIN A-1 PHOSPHATE AND COMBRETASTATIN B-1 PHOSPHATE PRODRUGS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA,ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-1045853-A1 | SYNTHESIS OF COMBRETASTATIN A-4 PRODRUGS AND TRANS-ISOMERS THEREO F | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA acting for and on behalf of ARIZONA STATE UNIVERSITY (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035150-A1 | SYNTHESIS OF COMBRETASTATIN A-4 PRODRUGS AND TRANS-ISOMERS THEREO F | ARIZONA BOARD OF REGENTS, A BODY CORPORATE, ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 1999-07-15 | — | — | WO | disclosed |
| US-4242479-A | CATALYST OF ALUMINUM TRIHALIDE, ORGANOSILOXANE COMPOUND OR ETHER, MAGNESIUM ALCOHOLATE, TITANIUM-HALOGEN AND ORGANOALUMINUM COMPOUNDS | SHOWA YUKA KABUSHIKI KAISHA (JP) | 1980-12-30 | — | — | US | disclosed |
| US-4180636-A | MAGNESIUM HALIDE, TITANIUM COMPOUND ELECTRON DONOR COMPOUND, TRIALKYL ALUMINUM CATALYST | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1979-12-25 | — | — | US | disclosed |
| US-4163781-A | 3-Amino-N-[(phosphonoamino)iminomethyl]-6-halopyrazinecarboxamide compounds, compositions and methods of use | MERCK & CO., INC. (US) | 1979-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570621-B2 | Short-acting 3,4-methylenedioxymethamphetamine (MDMA) analogs incorporating benzothiazole | SLC6A3, SLC6A2, HTR2C | TSHR 431/4885IDO1 4397/4885AGXT 1989/4885 |
| US-20250121067-A1 | WATER-SOLUBLE CANNABINOID PRODRUGS COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | CNR2, CNR1, BSG | TSHR 3388/4885IDO1 1896/4885AGXT 1033/4885 |
| US-12358919-B2 | Antibacterial compounds | ABCB11, CFTR, MRPL21 | TSHR 4772/4885IDO1 1087/4885AGXT 740/4885 |
| US-20250207163-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | RNGTT, POLRMT, POLN | TSHR 2116/4885IDO1 3983/4885AGXT 901/4885 |
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | HTR2C, SLC6A2, DRD2 | TSHR 610/4885IDO1 3819/4885AGXT 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.